Epigenomics AG, the German-American cancer molecular diagnostics company, presented promising data from a study using a proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer. The results were presented at Epigenomics’ Corporate Workshop and in a poster session at the Association for Molecular Pathology (AMP) 2015 Annual Meeting in Austin, Texas.
“We are very excited about the potential for a new blood-based test to enable the detection and subsequent timely treatment of lung cancer,” said Dr Uwe Staub, COO of Epigenomics AG. “Given the excellent sensitivity demonstrated in comparison with commonly used biomarkers, this test may also show significant clinical utility in combination with current imaging techniques.”
Epigenomics’ DNA methylation biomarker panel, including the SHOX2, FOXL2 and PTGER4 genes, was compared with two proteins commonly reported as lung cancer biomarkers. Levels of DNA methylation were analysed in two independent case-control sets of plasma samples. The training set (30 plasma samples) and the larger testing study (151 plasma samples) included all major histological types and covered a broad range of lung cancer stages (IA to IV).
The DNA methylation panel displayed high sensitivity in detecting lung cancer. The findings observed in the training study were confirmed in the testing study. Test sensitivity was reported at 95% with a specificity of 64%, thus allowing its use as a confirmatory test for positively tested patients in a low dose spiral computed tomography (LDCT) screening.
About lung cancer: According to the World Health Organization, lung cancer is the leading cause of cancer death worldwide. The vast majority of cases of lung cancer result from the long-term exposure to tobacco smoke. Early detection and treatment of lung cancer can save lives: survival rates for patients with lung cancer fall as the stage at diagnosis becomes more advanced.
About Epigenomics: Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the early detection of colorectal cancer. Epi proColon is currently marketed in Europe and China. For more information, visit www.epigenomics.com.